GCTK — Glucotrack, Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1506983 ·
Last close
$0.59
Market Cap
$3.72M
52W High
$1.67
52W Low
$0.43
ADV30
7,544,683
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -4,203,000 | -4,334,000 | 4,356,000 | 3,929,000 | 5,207,000 |
| Dec 2025 | 0 | — | -3,487,000 | -3,628,000 | 7,838,000 | 7,383,000 | 5,010,000 |
| Sep 2025 | 0 | — | -4,309,000 | -4,171,000 | 8,290,000 | 7,869,000 | 5,539,000 |
| Jun 2025 | 0 | — | -4,796,000 | -4,756,000 | 10,210,000 | 9,555,000 | 3,330,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,240,000
Investing CF
$-96,000
Financing CF
$17,043,000
CapEx
$-129,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1146.46
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-151,838,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-16,090,000
Pretax Income TTM
$-19,388,000
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -16,090,000 | -19,388,000 | 7,838,000 | 5,010,000 | — | -15,240,000 |
| Dec 2024 | 0 | -14,547,000 | -22,597,000 | 5,932,000 | 18,932,000 | — | -12,490,000 |
| Dec 2023 | 0 | -7,104,000 | -7,097,000 | 4,905,000 | 1,708,000 | — | -6,558,000 |
| Dec 2022 | 0 | -4,432,000 | -4,435,000 | 2,438,000 | 1,208,000 | — | -3,729,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SNOA | Sonoma Pharmaceuticals, Inc. | $3.68M | $1.06 | — |
| AEMD | AETHLON MEDICAL INC | $3.84M | $2.45 | — |
| TUTH | Standard Dental Labs Inc. | $3.88M | $0.12 | — |
| BTCY | BIOTRICITY INC. | $4.07M | $0.14 | — |
| GEGP | GOLD ENTERPRISE GROUP INC | $3.36M | $0.00 | — |
News headlines (Yahoo Finance, 1h cache)
Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific Sessions
2026-05-26 12:00 · Yahoo
Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
2026-05-14 21:27 · Yahoo
Glucotrack Submits Blood Glucose Monitoring Technology to FDA
2026-05-07 19:50 · Yahoo
Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology
2026-05-07 17:00 · Yahoo
Glucotrack Shows Long-Term Accuracy of Implantable Glucose Monitor
2026-04-30 20:56 · Yahoo
Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology
2026-04-30 13:00 · Yahoo
Study Supports GlucoTrack’s Blood Glucose Monitoring Implant
2026-04-21 15:59 · Yahoo
Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology
2026-04-21 12:00 · Yahoo
Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
2026-03-30 20:50 · Yahoo
Glucotrack to File for FDA Exemption Based on 2025 Milestones
2026-03-28 01:59 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.